Supplementary Table 1. Genotyping results in women with rCIN
ID rCIN Baseline T1 T2 T3 Conclusion
49 rCIN after CIN3 16 16 Persistence
50 rCIN after CIN3 35 35 Persistence
51 rCIN after CIN3 16 16 16 Persistence
52 rCIN after CIN3 16 31, 33 Type switch
53 rCIN after CIN3 51 45 Type switch
54 rCIN after CIN3 33 33 Persistence
55 rCIN after CIN3 35 35 Persistence
56 rCIN after CIN3 16, 18, 31, 59 68 45, 59 Type switch
57 rCIN after CIN3 Neg Neg HPV negative
58 rCIN after CIN3 Neg Neg HPV negative
59 rCIN after CIN2 51 Neg Neg Neg Clearance
60 rCIN after CIN2 31, 33 31 Persistence
Supplementary Table 2. Correlation between baseline lesion size and follow-up histology results
Follow-up Total
≤CIN1 17 35% 25 52% 6 13% 0 0% 48
rCIN2/3 3 25% 3 25% 5 42% 1 8% 12
Total 20 33% 28 47% 11 18% 1 2% 60
Lesion size is reported as no lesion visible, <25%, 25 – 50% or 50 – 75% of the transformation zone Lesion size
No lesion
visible <25% 25-50% 50-75%
Sensitivity p value Significant?
Strategy 1 vs 2 1 NS
Strategy 1 vs 3 0.625 NS
Strategy 1 vs 4 1 NS
Strategy 1 vs 5 1 NS
Strategy 1 vs 6 1 NS
Specificity p value Significant?
Strategy 1 vs 2 0.332 NS
Strategy 1 vs 3 <0.001 Sig
Strategy 1 vs 4 0.727 NS
Strategy 1 vs 5 0.332 NS
Strategy 1 vs 6 0.096 NS
PPV p value Significant?
Strategy 1 vs 2 0.149 NS
Strategy 1 vs 3 <0.001 Sig
Strategy 1 vs 4 0.510 NS
Strategy 1 vs 5 0.357 NS
Strategy 1 vs 6 0.125 NS
1-NPV p value Significant?
Strategy 1 vs 2 0.221 NS
Strategy 1 vs 3 0.472 NS
Strategy 1 vs 4 0.944 NS
Strategy 1 vs 5 0.403 NS
Strategy 1 vs 6 0.479 NS
Supplementary Table 3. Comparison of performance of ASCL1/LHX8 methylation analysis with the other screening strategies
Strategy 1: ASCL1/LHX8 methylation analysis, strategy 2: HPV, strategy 3: Cytology (≥HSIL), strategy 4: Cytology (≥ASCUS), strategy 5: HPV and/or cytology (≥HSIL), strategy 6: HPV and/or cytology (≥ASCUS)
